AML

This study is testing the safety of using cord blood for transplants in children and young adults (up to age 21) with life-threatening blood cancers or genetic blood disorders who do not have a perfectly matched donor. The main goal is to measure how many patients survive the fir…

This is an early-stage study to test the safety and find the right dose of a new experimental drug, JAB-8263, in adults with advanced cancers that have not responded to standard treatments. The trial will enroll about 152 people with various advanced solid tumors (like lung or ov…

This early-stage study is testing the safety and best dose of two oral drugs, CC-486 and venetoclax, for adults with acute myeloid leukemia (AML) that has come back or hasn't responded to prior treatment. The main goal is to find the highest dose patients can tolerate without sev…

This study is testing a new combination of three drugs (venetoclax, ivosidenib, and azacitidine) for adults with a specific genetic form of acute myeloid leukemia (AML) who are eligible for intensive chemotherapy. The main goals are to find the safest dose of this triple-drug reg…

This study will monitor 1,000 people for 15 years after they received an experimental T-cell therapy for blood cancers like leukemia. The goal is to track long-term safety and see how well the treatment continues to work over time. No new treatment is given in this study; researc…

This study is testing a combination of three drugs (gilteritinib, venetoclax, and azacitidine) for adults and teens newly diagnosed with a fast-growing blood cancer called AML, who have a specific genetic change (FLT3 mutation) and are healthy enough for strong treatment. The mai…

This study aims to find the better drug combination for preventing graft-versus-host disease (GVHD), a serious complication, after a stem cell transplant for blood cancers like AML. Researchers will compare two different three-drug regimens in about 80 participants aged 65-75. Th…

This study is testing a new immune cell therapy for children and young adults (up to age 40) with high-risk acute myeloid leukemia (AML). The goal is to see if giving specially prepared 'memory-like' natural killer (NK) cells from a partially matched family donor is safe and poss…

This is the first-ever study in people of an experimental treatment called CER-1236 for acute myeloid leukemia (AML) that has come back or is resistant to other treatments. Doctors will test the safety and early effectiveness of this therapy, which uses a patient's own immune cel…

This study is testing whether a two-drug treatment given after a bone marrow transplant can help prevent leukemia and related blood cancers from coming back. It involves children and young adults up to age 39 who have had a transplant for conditions like acute myeloid leukemia (A…

This is a first-in-human study to test a new drug called CG009301 in adults with blood cancers that have returned or stopped responding to standard treatments. The main goals are to find a safe dose and see how the body processes the drug. About 45 participants will receive the t…

This early-stage trial is testing whether adding an experimental drug called ziftomenib to standard leukemia treatments is safe and tolerable for patients. It focuses on adults with acute myeloid leukemia (AML) that has returned or not responded to prior therapy and has specific …

This study aims to discover new genes that cause cancer to run in families, especially those affecting children. Researchers will collect health information, blood, and sometimes leftover tumor samples from families where multiple members have had cancer. The goal is to build a l…

This study aims to understand how a cancer drug called venetoclax works in the body when it's given as a liquid made from crushed tablets. It will enroll up to 30 children and young adults with blood cancers who are already receiving this liquid form because they cannot swallow p…

This study aims to find a better way to predict which AML patients will respond well to chemotherapy. Researchers will measure levels of a hormone called leptin in the bone marrow fluid of 86 newly diagnosed patients. The goal is to see if high leptin levels are linked to poorer …